In an international multicenter study, combining FC with C-reactive proteins facilitated the assessment of upadacitinib’s efficacy and safety as an induction therapy for pediatric UC or IBD-U, with patients achieving normal C-reactive protein levels and FC values < 150 mcg/g reaching remission rates of 75% and 50%, respectively. Here, CRP is linked to irritable bowel syndrome.